CRISPR Therapeutics' Zugo-cel Shows Clinical Response in 5 of 6 Systemic Sclerosis Patients Receiving Standard Lymphodepletion

By Public Technologies
  • CRISPR Therapeutics reported encouraging preliminary results for investigational CAR-T therapy zugo-cel in a Phase 1 trial targeting refractory autoimmune diseases.
  • Systemic sclerosis results already presented at ACR Convergence 2026 showed most patients receiving standard lymphodepletion responded; all responders maintained improvement.
  • All nine inflammatory myopathy patients improved; two of three evaluable lupus patients maintained drug-free remission through at least nine months.
  • Zugo-cel was well tolerated across 21 patients as of October 15, 2026, with no dose-limiting toxicities or deaths reported.
  • Dose escalation remains ongoing across the rheumatology trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081030PRIMZONEFULLFEED9872813) on November 08, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk